• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Beyond Air Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    3/28/25 4:05:16 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care
    Get the next $XAIR alert in real time by email
    false 0001641631 0001641631 2025-03-24 2025-03-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of report (Date of earliest event reported): March 24, 2025

     

    Beyond Air, Inc.

    (Exact Name of Registrant as Specified in Charter)

     

    Delaware   001-38892   47-3812456

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    900 Stewart Avenue, Suite 301

    Garden City, NY 11530

    (Address of Principal Executive Offices and Zip Code)

     

    (516) 665-8200

    Registrant’s Telephone Number, Including Area Code

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $.0001 per share   XAIR   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    NeuroNOS Limited (“NeuroNos”), a wholly owned subsidiary of Beyond Air, Inc.’s (the “Company”) wholly owned subsidiary Beyond Air Ireland Limited (“Beyond Air Ireland”), previously entered into an agreement to sell ordinary shares pursuant to a subscription agreement by and among NeuroNos, Beyond Air Ireland and the lead investor signatory thereto (the “Subscription Agreement”). The Subscription Agreement provides for an initial closing of at least $2 million and one or more additional closings for up to an aggregate of $5 million in gross proceeds. Effective March 24, 2025, additional investors signed the Subscription Agreement with the initial closing of $2 million expected to be on March 31, 2025. Following the initial closing of $2 million, Beyond Air Ireland shall own approximately 88% of NueroNos, and, if all $5 million ordinary shares are sold, Beyond Air Ireland shall own approximately 75% of NeuroNos. In connection with the Subscription Agreement, the parties thereto entered into a shareholders agreement effective March 31, 2025 (the “Shareholders Agreement”) that outlines the rights and obligations of the shareholders of NeuroNos.

     

    The foregoing description of the Subscription Agreement and the Shareholders Agreement is not complete and is qualified in its entirety by reference to the full text of the Subscription Agreement and the Shareholders Agreement, copies of which will be filed as exhibits to the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2025.

     

    Item 8.01 Other Events

     

    On March 24, 2025, a press release was issued to announce the transaction described above in Item 1.01. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit

    No.

      Description

    99.1

      Press Release dated March 24, 2025.
    104   Cover Page Interactive Data File (embedded within the inline XBRL document).

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      BEYOND AIR, Inc.
       
    Date: March 28, 2025 By: /s/ Steven A. Lisi
      Name: Steven A. Lisi
      Title Chief Executive Officer

     

     

    Get the next $XAIR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XAIR

    DatePrice TargetRatingAnalyst
    6/25/2024Buy → Neutral
    BTIG Research
    7/28/2023$10.00Overweight
    Piper Sandler
    6/15/2023$15.00Buy
    BTIG Research
    11/12/2021$12.00 → $16.00Buy
    Truist Securities
    More analyst ratings

    $XAIR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Operating Officer Gaul Michael A.

      4 - Beyond Air, Inc. (0001641631) (Issuer)

      3/28/25 5:12:57 PM ET
      $XAIR
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Lee Yoori

      4 - Beyond Air, Inc. (0001641631) (Issuer)

      3/28/25 5:12:58 PM ET
      $XAIR
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Lucera Erick

      4 - Beyond Air, Inc. (0001641631) (Issuer)

      3/28/25 5:12:59 PM ET
      $XAIR
      Medical/Dental Instruments
      Health Care

    $XAIR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer's Disease and Reinforcing Platform's Strength Across Neurological Disorders

      BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company developing transformative treatments for complex neurological disorders, including Autism Spectrum Disorder (ASD), brain cancers, and Alzheimer's disease, and a subsidiary of Beyond Air (NASDAQ:XAIR), proudly announces the publication of breakthrough research by its Chief Scientific Officer, Prof. Haitham Amal, in Translational Psychiatry, a peer-reviewed medical journal published by Nature Publishing Group. The article, which is titled, "Shared Early Molecular Mechanisms Revealed in P301S and 5xFAD Alzheimer's Disease Mouse Models," presents compelling evidence of a novel mechanism in the early sta

      4/1/25 8:00:00 AM ET
      $XAIR
      Medical/Dental Instruments
      Health Care
    • NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy

      First-in-human studies anticipated to begin in 2026 Engaged a top tier U.S. based contract manufacturer to ensure the highest standards of quality Currently in the advanced stages of formulation development for subcutaneous injection, with plans for an oral formulation BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company focused on developing transformative treatments for Autism Spectrum Disorder (ASD) and other complex neurological conditions, including Alzheimer's disease and brain cancers, and a subsidiary of Beyond Air (NASDAQ:XAIR), has secured an initial $2 million in equity financing from private investors as part of a larger funding round.

      3/24/25 4:05:00 PM ET
      $XAIR
      Medical/Dental Instruments
      Health Care
    • Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy

      The Phase 1b study will evaluate LV UNO in unresectable cutaneous or subcutaneous histologically confirmed primary or metastatic solid tumor cancer patients that have progressed or have prolonged stable disease on single agent PD-1 inhibitorsThe primary objective of the Phase 1b study is to assess preliminary efficacy by objective response rate (ORR) and duration of response (DOR) per RECIST version 1.1 and secondarily immune-related response via iRECISTThe study will recruit patients from four sites across Israel HAMILTON, Bermuda, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical-stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an imm

      12/3/24 4:05:00 PM ET
      $XAIR
      Medical/Dental Instruments
      Health Care

    $XAIR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Carey Robert bought $250,050 worth of shares (1,000,000 units at $0.25), increasing direct ownership by 33% to 4,076,864 units (SEC Form 4)

      4 - Beyond Air, Inc. (0001641631) (Issuer)

      3/17/25 8:15:33 AM ET
      $XAIR
      Medical/Dental Instruments
      Health Care
    • Chief Operating Officer Gaul Michael A. bought $2,294 worth of shares (6,000 units at $0.38), increasing direct ownership by 7% to 94,150 units (SEC Form 4)

      4 - Beyond Air, Inc. (0001641631) (Issuer)

      2/21/25 5:00:14 PM ET
      $XAIR
      Medical/Dental Instruments
      Health Care
    • Director Carey Robert bought $744,662 worth of shares (1,476,626 units at $0.50) (SEC Form 4)

      4 - Beyond Air, Inc. (0001641631) (Issuer)

      10/1/24 9:58:10 PM ET
      $XAIR
      Medical/Dental Instruments
      Health Care

    $XAIR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • July 1, 2022 - FDA Roundup: July 1, 2022

      For Immediate Release: July 01, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a request for nominations for consumer representatives to serve on advisory committees and panels for which vacancies currently exist or are expected to occur in the near future. The FDA relies on our many advisory committees to help us

      7/1/22 11:54:25 AM ET
      $XAIR
      Medical/Dental Instruments
      Health Care

    $XAIR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Beyond Air downgraded by BTIG Research

      BTIG Research downgraded Beyond Air from Buy to Neutral

      6/25/24 8:04:46 AM ET
      $XAIR
      Medical/Dental Instruments
      Health Care
    • Piper Sandler initiated coverage on Beyond Air with a new price target

      Piper Sandler initiated coverage of Beyond Air with a rating of Overweight and set a new price target of $10.00

      7/28/23 7:37:57 AM ET
      $XAIR
      Medical/Dental Instruments
      Health Care
    • BTIG Research initiated coverage on Beyond Air with a new price target

      BTIG Research initiated coverage of Beyond Air with a rating of Buy and set a new price target of $15.00

      6/15/23 7:39:48 AM ET
      $XAIR
      Medical/Dental Instruments
      Health Care

    $XAIR
    Leadership Updates

    Live Leadership Updates

    See more
    • Beyond Cancer™ Announces the Appointment of Jedidiah Monson, M.D. to Chief Medical Officer

      Dr. Monson is a board-certified radiation oncologist and brings over 25 years of clinical oncology experience to Beyond Cancer. Dr. Monson is a founding partner and President of California Cancer Associates for Research & Excellence (cCARE), the largest private oncology practice in California. HAMILTON, Bermuda, June 01, 2022 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ:XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced the appointment of Jedidiah Monson, M.D. to the position of Chief Medical Officer, effective June 1, 2022. "We are excited to appoint Dr. Monson as

      6/1/22 7:00:00 AM ET
      $XAIR
      Medical/Dental Instruments
      Health Care
    • Beyond Cancer, Ltd. Appoints Susan Howell Jones, CPA as Chief Financial Officer

      HAMILTON, Bermuda, May 17, 2022 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ:XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced the appointment of Susan Howell Jones, CPA as Chief Financial Officer. Ms. Jones joins Beyond Cancer™ with over 30 years of international and operational financial leadership experience, including 20 years within the bioscience sector of BASF, a globally recognized chemical company. In her role as Senior Manager of Operational Accounting she was a key member of the implementation team responsible for the $4B acquisition of American Cyanamid. Follow

      5/17/22 7:00:00 AM ET
      $XAIR
      Medical/Dental Instruments
      Health Care
    • Beyond Air® Expands Leadership Team with the Appointment of Dr. Andrew Colin to Chief Medical Officer

      Dr. Colin brings four decades of clinical experience in pediatric pulmonology to Beyond Air, with research spanning respiratory physiology, Cystic Fibrosis, and lung infections culminating in over 120 peer-reviewed publications and 250 global lectures As a board-certified pediatric pulmonologist, Dr. Colin has been an active member of Beyond Air's Scientific Advisory Board since 2013 Dr. Colin has participated in over 20 clinical trials, including studies sponsored by the National Institutes of Health, Genentech, GlaxoSmithKline, and the Cystic Fibrosis Foundation's Therapeutic Development Network GARDEN CITY, N.Y., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a c

      12/1/21 8:00:00 AM ET
      $XAIR
      Medical/Dental Instruments
      Health Care

    $XAIR
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Beyond Air Inc.

      DEF 14A - Beyond Air, Inc. (0001641631) (Filer)

      5/5/25 4:45:04 PM ET
      $XAIR
      Medical/Dental Instruments
      Health Care
    • SEC Form PRE 14A filed by Beyond Air Inc.

      PRE 14A - Beyond Air, Inc. (0001641631) (Filer)

      4/25/25 5:20:21 PM ET
      $XAIR
      Medical/Dental Instruments
      Health Care
    • Beyond Air Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - Beyond Air, Inc. (0001641631) (Filer)

      3/28/25 4:05:16 PM ET
      $XAIR
      Medical/Dental Instruments
      Health Care

    $XAIR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Beyond Air Inc.

      SC 13G/A - Beyond Air, Inc. (0001641631) (Subject)

      10/9/24 1:35:29 PM ET
      $XAIR
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Beyond Air Inc.

      SC 13G - Beyond Air, Inc. (0001641631) (Subject)

      10/3/24 3:09:56 PM ET
      $XAIR
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Beyond Air Inc.

      SC 13G - Beyond Air, Inc. (0001641631) (Subject)

      3/7/24 12:29:51 PM ET
      $XAIR
      Medical/Dental Instruments
      Health Care

    $XAIR
    Financials

    Live finance-specific insights

    See more
    • Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast

      GARDEN CITY, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients, today announced that it plans to report the financial results for the second quarter of its fiscal year 2025 ended September 30, 2024 on Monday, November 11, 2024 after the market closes. Conference Call & WebcastMonday, November 11th @ 4:30 PM ETDomestic: 1-877-407-0784International: 1-201-689-8560Conference ID: 13749670Webcast: A webcast of the live conference call can be accessed by visiting the Eve

      10/29/24 4:22:08 PM ET
      $XAIR
      Medical/Dental Instruments
      Health Care
    • Beyond Air® Reports Financial Results for Fourth Fiscal Quarter and Year-End 2022

      LungFit® PH received FDA approval for the treatment of term and near-term neonates with hypoxic respiratory failure on June 28, 2022 and the first phase of U.S. commercial launch has begun Presented positive data for high-concentration nitric oxide (NO) with LungFit® PRO in hospitalized patients with community-acquired viral pneumonia, including COVID-19, at ECCMID 2022 Presented positive long-term safety data for high-concentration NO at PAS 2022 in infants hospitalized with bronchiolitis Presented positive updated interim data from the ongoing at-home LungFit® GO pilot study for nontuberculous mycobacterial lung disease at ATS 2022 Patient screening has begun for the Phase I trial of

      6/28/22 4:10:00 PM ET
      $XAIR
      Medical/Dental Instruments
      Health Care
    • Beyond Air® Announces Fiscal Year End 2022 Financial Results Conference Call and Webcast Moved to Tuesday, June 28th

      GARDEN CITY, New York, June 14, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that it has rescheduled the reporting of the financial results for its fiscal fourth quarter and year ended March 31, 2022 to Tuesday, June 28, 2022. The Company's management team will also host its quarterly conference call and webcast at 4

      6/14/22 4:30:00 PM ET
      $XAIR
      Medical/Dental Instruments
      Health Care